Last update 16 Aug 2026
Guangzhou Bosto Controlled-Release Pharmaceutical Co Ltd.

Guangzhou Bosto Controlled-Release Pharmaceutical Co Ltd.

Joint Venture Company | Subsidiary Company|2013|Guangdong Sheng, China|
www.bostaldrug.com

Overview

Tags

Urogenital Diseases
Nervous System Diseases
Skin and Musculoskeletal Diseases
Small molecule drug

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Nervous System Diseases2
Immune System Diseases2
Endocrinology and Metabolic Disease1
Top 5 Drug TypeCount
Small molecule drug8
Top 5 TargetCount
JAK(Janus kinase)3
mAChRs(Muscarinic acetylcholine receptor)1

Related

8
Drugs associated with Guangzhou Bosto Controlled-Release Pharmaceutical Co Ltd.
Fesoterodine Fumarate
Target
mAChRs
Mechanism
mAChRs antagonists
Active Org.
Pfizer Inc.Pfizer Inc. [+4]
Originator Org.
Pfizer Inc.Pfizer Inc.
Active Indication
Urinary Bladder, Neurogenic [+6]
Inactive Indication
Autonomic Dysreflexia [+5]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
European Union [+3]
First Approval Date20 Apr 2007
Tofacitinib etocomil
Target
JAK
Mechanism
JAK inhibitors
Active Org.
Guangzhou Bosto Controlled-Release Pharmaceutical Co Ltd.Guangzhou Bosto Controlled-Release Pharmaceutical Co Ltd. [+1]
Originator Org.
Minghui Pharmaceutical (Shanghai) Ltd.
Active Indication
Nonsegmental vitiligo [+2]
Inactive Indication
Autoimmune Diseases [+1]
Drug Highest PhaseNDA/BLA
First Approval Ctry. / Loc.-
First Approval Date-
AP-016
Target-
Mechanism-
Active Org.
Guangzhou Bosto Controlled-Release Pharmaceutical Co Ltd.Guangzhou Bosto Controlled-Release Pharmaceutical Co Ltd.
Originator Org.
Guangzhou Bosto Controlled-Release Pharmaceutical Co Ltd.Guangzhou Bosto Controlled-Release Pharmaceutical Co Ltd.
Active Indication
Migraine Disorders
Inactive Indication-
Drug Highest PhasePreclinical
First Approval Ctry. / Loc.-
First Approval Date-
20
Clinical Trials associated with Guangzhou Bosto Controlled-Release Pharmaceutical Co Ltd.
NCT07742280
/ Not yet recruitingPhase 2/3
An Open-Label, Multi-Center Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Brexpiprazole for Extended-Release Injection Administered as a Single Dose in Subjects With Schizophrenia
NCT07722728
/ Not yet recruitingPhase 2/3
An Open-label, Randomized, Single-dose (Long-acting Injectable) or Multiple-dose (Oral) Clinical Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of B2227 Extended-Release Injectable Suspension and Vraylar® in Participants With Schizophrenia
CTR20253263
/ CompletedNot Applicable
注射用醋酸亮丙瑞林微球在绝经后女性参与者中的随机、开放、单剂量、平行设计的药代动力学对比研究
[Translation] A randomized, open-label, single-dose, parallel-design comparative pharmacokinetic study of leuprorelin acetate microspheres for injection in postmenopausal women
100 Clinical Results associated with Guangzhou Bosto Controlled-Release Pharmaceutical Co Ltd.
Login to view more data
0 Patents (Medical) associated with Guangzhou Bosto Controlled-Release Pharmaceutical Co Ltd.
Login to view more data
100 Deals associated with Guangzhou Bosto Controlled-Release Pharmaceutical Co Ltd.
Login to view more data
100 Translational Medicine associated with Guangzhou Bosto Controlled-Release Pharmaceutical Co Ltd.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 16 Aug 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Preclinical
6
1
Phase 3
NDA/BLA
1
1
Other
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
Fesoterodine Fumarate
 ( mAChRs )		Pollakisuria
More
Phase 3
AP-016
Migraine Disorders
More
Preclinical
BST-RD066
Diabetes Mellitus
More
Preclinical
BST-2227
Schizophrenia
More
Preclinical
BST-RD064
Dermatitis, Atopic
More
Preclinical
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free